(Q38818713)

6 September 2017

title

Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects (English)

1 reference

6 September 2017

Yuval Shaked

1

1 reference

6 September 2017

language of work or name

English

0 references

publication date

26 April 2016

1 reference

Nature Reviews Clinical Oncology

6 September 2017

published in

1 reference

6 September 2017

volume

13

1 reference

6 September 2017

issue

10

1 reference

6 September 2017

page(s)

611-626

1 reference

Adverse events to nontargeted and targeted chemotherapeutic agents: emphasis on hypersensitivity responses

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Adverse effects of anticancer agents that target the VEGF pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Pharmacology of cytotoxic agents: a helpful tool for building dose adjustment guidelines in the elderly.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Practical treatment guide for dose individualisation in cancer chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Accessories to the crime: functions of cells recruited to the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Repopulation of cancer cells during therapy: an important cause of treatment failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Tumor resistance to therapy: a genetic or kinetic problem?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Disrupting tumour blood vessels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

High infiltration of tumor-associated macrophages is associated with a poor response to chemotherapy and poor prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

The tumour stromal features are associated with resistance to 5-FU-based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

DNA damage-mediated induction of a chemoresistant niche

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Host effects contributing to cancer therapy resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Mesenchymal Stem Cells Induce Resistance to Chemotherapy through the Release of Platinum-Induced Fatty Acids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Chemotherapy Enhances Metastasis Formation via VEGFR-1–Expressing Endothelial Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Dying tumor cells stimulate proliferation of living tumor cells via caspase-dependent protein kinase Cδ activation in pancreatic ductal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Cell death-stimulated cell proliferation: a tissue regeneration mechanism usurped by tumors during radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Radiotherapy: Repopulating tumor cells--dying for caspase 3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Cancer immunotherapy – revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Peering into the aftermath: The inhospitable host?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Pathways mediating resistance to vascular endothelial growth factor-targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Adjuvant bevacizumab in colon cancer: where did we go wrong?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Surgical treatment of early-stage carcinoma of the oral tongue--wound adjuvant treatment be beneficial?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Failure at distant sites following multimodality treatment for advanced head and neck cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Molecular pathways: emerging pathways mediating growth, invasion, and metastasis of tumors progressing in an irradiated microenvironment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Tumor response to radiotherapy regulated by endothelial cell apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Vascular Activation of Adhesion Molecule mRNA and Cell Surface Expression by Ionizing Radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Targeting hypoxia in cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Targeting HIF-1 for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Vasculogenesis: a crucial player in the resistance of solid tumours to radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Mobilization of circulating vascular progenitors in cancer patients receiving external beam radiation in response to tissue injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Combining angiogenesis inhibition and radiotherapy: a double-edged sword

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Macrophage regulation of tumor responses to anticancer therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Enhanced activity of the macrophage-like cell line J774.1 following exposure to gamma radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Microenvironmental regulation of metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Irradiation promotes an m2 macrophage phenotype in tumor hypoxia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Inflammation meets cancer, with NF-κB as the matchmaker

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Pre-irradiation of mouse mammary gland stimulates cancer cell migration and development of lung metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Radiation acts on the microenvironment to affect breast carcinogenesis by distinct mechanisms that decrease cancer latency and affect tumor type

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

New radiation techniques for treatment of locally advanced non-small cell lung cancer (NSCLC).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - Association of interleukin-8 and VEGF with survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

History of Cancer, Ancient and Modern Treatment Methods

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Tumor cell seeding during surgery-possible contribution to metastasis formations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Circulating tumor cells before and during follow-up after breast cancer surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Wound repair and regeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

31 March 2020

Wounds and malignancy

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Surgery, wound healing, and metastasis: recent insights and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

A surgically induced hypoxic environment causes changes in the metastatic behaviour of tumours in vitro.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Does Surgery for Breast Cancer Induce Angiogenesis and Thus Promote Metastasis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

"The air got to it:" exploring a belief about surgery for lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

"Cutting" on cancer: attitudes about cancer spread and surgery among primary care patients in the U.S.A.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Excisional surgery for cancer cure: therapy at a cost

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-β) in Patients with Breast Cancer Who Underwent Limited or Ex

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Laparoscopic and open surgery for colorectal cancer: reaching equipoise?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Stimulation of tumour growth by wound-derived growth factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Inflammation-mediated promotion of invasion and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Laparoscopic surgery for colorectal cancer is not associated with an increase in the circulating levels of several inflammation-related factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Systemic and peritoneal inflammatory response after laparoscopic-assisted gastrectomy and the effect of inflammatory cytokines on adhesion of gastric cancer cells to peritoneal mesothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Mechanism of Surgical Stress Impairment of Human Perioperative Natural Killer Cell Cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

New aspects of natural-killer-cell surveillance and therapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Correlation of Circulating Angiogenic Factors with Circulating Tumor Cells and Disease Recurrence in Patients Undergoing Curative Resection for Colorectal Liver Metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Laparoscopic surgery minimizes the surgical manipulation of isolated tumor cells leading to decreased metastasis compared to open surgery for colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

A phase 3 trial of bevacizumab in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Macrophage inflammatory protein-3 alpha (MIP-3a) is a novel serum prognostic marker in patients with colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Macrophages and therapeutic resistance in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Metronomic chemotherapy: new rationale for new directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

When less is more: maintenance therapy in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Dual role of immunomodulation by anticancer chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Blocking IL1β Pathway Following Paclitaxel Chemotherapy Slightly Inhibits Primary Tumor Growth but Promotes Spontaneous Metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Why not treat human cancer with interleukin-1 blockade?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Metastasis risk after anti-macrophage therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Pharmacogenetics and breast cancer management: current status and perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Drug repurposing in oncology--patient and health systems opportunities.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Drug-induced myelosuppression : diagnosis and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Antiangiogenic therapy--evolving view based on clinical trial results.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.57

Promotion of pulmonary metastasis in mice by bleomycin-induced endothelial injury.

31 March 2020

1 reference

12 December 2020

Exposure to gamma-irradiation increases phorbol myristate acetate-induced H2O2 production in human macrophages

1 reference

12 December 2020

Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil

1 reference

12 December 2020

Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches

1 reference

12 December 2020

Effect of laparoscopy on the immune system.

1 reference

12 December 2020

Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung

1 reference

12 December 2020

The price of anticancer intervention. Does surgery promote metastasis?

1 reference

12 December 2020

Monitoring of circulating tumor cells in patients undergoing surgery for hepatic metastases from colorectal cancer

1 reference

12 December 2020

Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil?

1 reference

12 December 2020

Dequalinium blocks macrophage-induced metastasis following local radiation

1 reference

12 December 2020

Macrophage content of murine sarcomas and carcinomas: associations with tumor growth parameters and tumor radiocurability

1 reference

12 December 2020

Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.

1 reference

12 December 2020

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

12 December 2020

The "seed and soil" hypothesis and the decline of radical surgery: a surgeon's opinion

1 reference

12 December 2020

10.1038/NRCLINONC.2016.57

Identifiers

DOI

1 reference

release_dcv2kd77y5gmxdmu7whvfl6rhe

6 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dcv2kd77y5gmxdmu7whvfl6rhe

24 November 2022

mapped directly with Wikidata item

1 reference